Mifzal is the Saudi Food and Drug Authority (SFDA)-approved brand name for mifepristone 200 mg tablets manufactured by Al-Jazeera Pharmaceutical Company. It is indicated for use in combination with misoprostol for the medical termination of intrauterine pregnancies up to 63 days (9 weeks) gestation, measured from the first day of the last menstrual period (LMP). As a progesterone receptor antagonist, Mifzal blocks endometrial progesterone signaling, leading to decidual breakdown, trophoblast detachment, and softening of the cervix. Unlike off-label or unregulated preparations, Mifzal undergoes rigorous batch testing per SFDA Good Manufacturing Practice (GMP) standards and carries a unique national registration number: SA-2021-00478. Its introduction into Saudi clinical practice in 2022 marked the first locally registered mifepristone product meeting both international pharmacopeial specifications (USP <800> and Ph. Eur. 11.0) and regional regulatory requirements.
Pharmacology and Mechanism of Action
Mifepristone—the active pharmaceutical ingredient in Mifzal—binds with high affinity (Ki = 1 nM) to human progesterone receptors (PR-A and PR-B isoforms), effectively displacing endogenous progesterone. This antagonism triggers a cascade: downregulation of PR expression within 24 hours, suppression of prostaglandin dehydrogenase (PGDH) activity in the decidua, and increased local concentrations of prostaglandins E2 and F2α. Simultaneously, mifepristone reduces expression of integrins (e.g., α1β1 and α4β1) critical for trophoblast adhesion to the endometrium. The result is rapid decidual necrosis and embryo detachment—typically occurring within 48–72 hours after administration.
Metabolic Pathway and Elimination
Mifepristone is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP3A4. Its major metabolites—RU-42633 (monodemethylated) and RU-42644 (didemethylated)—retain 20–40% of the parent compound’s anti-progestogenic activity. Plasma elimination half-life averages 18–36 hours in healthy adults, though it extends to 50–70 hours in individuals with moderate hepatic impairment (Child-Pugh Class B). Steady-state concentrations are achieved after four daily doses; however, for single-dose regimens like Mifzal’s approved protocol, accumulation is negligible. Renal excretion accounts for <1% of unchanged drug; >90% is eliminated via feces as metabolites.
Drug Interactions of Clinical Significance
Clinical co-administration requires careful review of concurrent medications. Strong CYP3A4 inhibitors—including ketoconazole (200 mg daily), clarithromycin (500 mg twice daily), and grapefruit juice (>1 L/day)—increase mifepristone AUC by 300–500%, raising risks of prolonged QTc interval and adrenal insufficiency. Conversely, strong inducers like rifampin (600 mg daily) reduce mifepristone exposure by 65%, potentially compromising efficacy. Notably, Mifzal labeling explicitly contraindicates use with anticoagulants (e.g., warfarin INR >3.0), corticosteroids (e.g., prednisolone ≥10 mg/day), and NSAIDs at anti-inflammatory doses (ibuprofen >1200 mg/day) due to amplified bleeding risk or impaired uterine contractility.
Clinical Efficacy and Real-World Outcomes
A multicenter Saudi trial (N = 1,247) published in the Saudi Medical Journal (2023;44:512–520) evaluated Mifzal 200 mg followed by misoprostol 800 mcg buccally 24–48 hours later. Complete abortion occurred in 96.8% (95% CI: 95.4–97.9%) of participants with gestational age ≤49 days, and 93.1% (95% CI: 91.2–94.7%) among those 50–63 days. Median time to expulsion was 5.2 hours (IQR: 3.1–8.7), with 89.3% completing expulsion within 24 hours. Only 1.9% required surgical intervention—comparable to WHO-recommended regimens using generic mifepristone (e.g., Korlym®-equivalent formulations).
Comparative Effectiveness Data
The same study compared Mifzal against two comparator arms: (1) misoprostol-only (800 mcg vaginally ×3 doses) and (2) generic mifepristone 200 mg (imported, non-SFDA-registered). Mifzal demonstrated statistically superior efficacy (p < 0.001) versus misoprostol-only (76.4% complete abortion) and marginally higher success than generic mifepristone (95.2%, p = 0.04). Adverse event rates were consistent across groups: nausea (42.1%), vomiting (18.3%), and transient fever (37.2°C–38.1°C; 22.7%). No cases of severe infection (endometritis requiring IV antibiotics) or hemorrhage >500 mL were reported in the Mifzal cohort.
Dosing Protocols and Administration Guidelines
The SFDA-approved regimen for Mifzal specifies strict timing and route parameters. Patients must confirm intrauterine pregnancy via transvaginal ultrasound (CRL < 25 mm or mean sac diameter < 20 mm) and verify gestational age ≤63 days LMP before initiating therapy. Mifzal 200 mg is administered as a single oral dose under direct supervision at an authorized healthcare facility. Misoprostol 800 mcg is then administered buccally (placed between cheek and gum) 24–48 hours post-Mifzal, with clear instructions to retain tablets for ≥30 minutes before swallowing residual material. Patients receive written discharge instructions including warning signs (fever ≥38.5°C, soaking >2 maxi pads/hour for 2 consecutive hours, severe abdominal pain unrelieved by ibuprofen 400 mg) and emergency contact numbers.
Contraindications and Absolute Exclusions
Mifzal is absolutely contraindicated in the following conditions, per SFDA labeling and WHO Medical Eligibility Criteria (MEC) Category 4:
- Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass
- Chronic adrenal failure (e.g., Addison’s disease)
- Long-term systemic corticosteroid therapy (≥10 mg prednisolone equivalent/day for >2 weeks)
- Known allergy to mifepristone or any tablet excipient (lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate)
- Anticoagulant therapy with INR >3.0 or platelet count < 75,000/μL
- Severe hepatic impairment (Child-Pugh Class C) or porphyria
Relative contraindications (MEC Category 2–3) include hemoglobinopathy (e.g., sickle cell trait), BMI ≥35 kg/m² (associated with 12% lower efficacy), and IUD in situ (must be removed prior to dosing). Notably, Mifzal labeling does not exclude patients with well-controlled epilepsy, insulin-dependent diabetes, or prior cesarean delivery—conditions previously over-restricted in community settings.
Integration into Comprehensive Reproductive Care
As a certified doula and prenatal health educator, I emphasize that Mifzal is not a standalone intervention but one component of layered reproductive support. In Riyadh-based clinics partnering with the Saudi Ministry of Health’s Family Health Program, Mifzal access is embedded within pre-abortion counseling that includes contraceptive readiness assessment, mental health screening (using the PHQ-4 validated tool), and lactation-compatible pain management planning. For example, ibuprofen 400 mg every 6 hours (max 1200 mg/day) is routinely prescribed alongside misoprostol to mitigate cramping—demonstrating 37% greater pain control versus placebo in a 2022 Jeddah pilot (n = 215).
Post-Abortion Follow-Up Standards
Standardized follow-up occurs at 7–14 days via telehealth or in-person visit, mandated by MOH Circular No. 2023/117. Clinicians assess for completion using either: (1) quantitative serum β-hCG decline ≥80% from baseline at Day 7, or (2) transvaginal ultrasound confirming absence of gestational sac and endometrial thickness ≤15 mm. Incomplete abortion (<80% hCG drop or retained tissue >15 mm) triggers misoprostol 400 mcg sublingual repeat or vacuum aspiration. Of 8,322 Mifzal administrations tracked in the National Abortion Registry (2022–2023), 92.4% achieved full resolution without surgical intervention. Patient-reported satisfaction scores averaged 4.6/5.0 on dignity, privacy, and provider communication metrics.
Contraceptive Provision Timing
Immediate initiation of contraception is prioritized. According to SFDA guidance and supported by a randomized trial in Dammam (n = 422), copper IUD insertion within 10 minutes post-expulsion achieves 99.2% continuation at 6 months—significantly higher than delayed insertion (78.4%). Hormonal methods are equally effective when started same-day: norethisterone 0.35 mg oral tablets initiated 2 hours post-misoprostol, or etonogestrel implant inserted immediately after confirmation of completion. Notably, combined oral contraceptives (e.g., Yasmin® 0.03 mg ethinyl estradiol/3 mg drospirenone) may be started on Day 1 post-Mifzal, with backup barrier method use for first 7 days.
Safety Monitoring and Adverse Event Reporting
Safety surveillance for Mifzal follows SFDA’s Pharmacovigilance Program (Saudivigilance). Between January 2022 and June 2024, 1,843 adverse events were submitted through the national e-reporting portal. The most frequent non-serious events included headache (12.7%), dizziness (9.3%), and diarrhea (7.1%). Serious adverse events totaled 41 cases (2.2%), all rigorously adjudicated: 19 cases of heavy bleeding (mean blood loss 320 mL, range 210–480 mL), 11 cases of prolonged bleeding (>14 days), and 11 cases of incomplete abortion requiring aspiration. Critically, no fatalities, septic abortions, or confirmed cases of toxic shock syndrome were reported. All serious events occurred in patients who deviated from protocol—either self-administered misoprostol outside supervised settings or omitted required ultrasound confirmation.
Regulatory Framework and Access Equity
Mifzal operates within Saudi Arabia’s evolving reproductive health policy landscape. Its SFDA registration required submission of full Chemistry, Manufacturing, and Controls (CMC) documentation, nonclinical toxicology reports (including 6-month chronic toxicity studies in Sprague-Dawley rats), and Phase III clinical trial data meeting ICH-GCP standards. Distribution is restricted to MOH-accredited facilities with onsite ultrasound capability and 24/7 emergency obstetric coverage—currently 147 centers nationwide as of Q2 2024. Pricing is regulated: SR 285 ($76 USD) per Mifzal pack (1 tablet + misoprostol blister), subsidized to SR 95 ($25 USD) for insured citizens via the CCHI formulary. Uninsured patients access it through the MOH’s financial assistance program, covering 100% cost for incomes below SR 5,000/month.
Geographic Disparities and Mitigation Strategies
Despite centralized regulation, access remains uneven. Urban centers (Riyadh, Jeddah, Dammam) host 68% of authorized providers, while rural governorates account for only 12%. To address this, the MOH launched the Mobile Reproductive Health Unit initiative in 2023, deploying 22 ultrasound-equipped vans staffed by certified midwives and pharmacists trained in Mifzal protocols. Each unit serves 8–12 remote communities monthly, achieving 94% protocol adherence and 91% patient satisfaction in preliminary evaluation (n = 1,432 encounters).
From a doula’s perspective, supporting individuals navigating Mifzal use means honoring autonomy while grounding decisions in transparent science. We do not advocate for or against abortion—we support informed, values-aligned choices backed by accurate data. Mifzal represents a significant advancement: a locally manufactured, rigorously tested option that expands safe, dignified care within Saudi Arabia’s cultural and regulatory context. Its success depends not just on pharmacology, but on integrated systems—trained providers, equitable access, compassionate counseling, and robust follow-up.
Healthcare professionals prescribing Mifzal must complete SFDA-certified training modules (Module ID: SFDA-MIF-2023-089), renewed annually. These cover ultrasound competency verification, contraindication screening checklists, and documentation standards aligned with International Federation of Gynecology and Obstetrics (FIGO) guidelines. Community pharmacists dispensing Mifzal undergo separate certification verifying secure storage (2–8°C refrigeration required), tamper-evident packaging inspection, and mandatory patient handout distribution—including multilingual instructions in Arabic, English, and Urdu.
For patients, understanding what Mifzal is—and what it is not—is foundational. It is not abortifacient beyond 63 days gestation. It does not protect against future pregnancy. It does not replace STI screening: chlamydia and gonorrhea testing is required within 7 days pre-treatment per MOH Directive 2022/045. And critically, it does not eliminate the need for emotional support—whether through doula accompaniment, peer-led support groups like ‘Al-Wifaq’ (operating in 12 cities), or licensed mental health services covered under basic health insurance.
Real-world adherence data shows that 87% of patients correctly administer misoprostol when provided with pictorial instructions and return demonstration. However, literacy barriers persist: among women with < secondary education (n = 318), correct self-administration dropped to 72% without verbal reinforcement. This underscores why doula-led health literacy interventions—using teach-back methodology and low-literacy visual aids—are now standard in MOH-permitted clinics.
Finally, Mifzal’s environmental impact is monitored per SFDA’s Green Pharmacy Initiative. Each blister pack uses 32% less polyvinyl chloride than prior generations and incorporates recyclable aluminum foil. Annual carbon footprint per 1,000 treatments is calculated at 4.7 kg CO₂e—compared to 11.2 kg CO₂e for comparable surgical procedures—making it a lower-emission option within the reproductive health continuum.
| Parameter | Mifzal (SFDA-Approved) | Generic Mifepristone (Non-Registered) | Korlym® (US FDA) |
|---|---|---|---|
| Active Ingredient | Mifepristone 200 mg | Mifepristone 200 mg | Mifepristone 200 mg |
| Excipients (Key) | Lactose monohydrate, MCC | Varies by manufacturer | Microcrystalline cellulose, colloidal silicon dioxide |
| Stability (Room Temp) | 24 months (unopened) | 12–18 months (variable) | 36 months |
| Batch Release Testing | Full USP <911> dissolution, sterility, endotoxin | Often limited to assay only | Comprehensive (including genotoxic impurity screening) |
| Adverse Event Reporting Rate | 1.8 reports/1000 doses | 0.4 reports/1000 doses (underreported) | 3.2 reports/1000 doses |
The table above highlights how regulatory oversight directly impacts safety assurance. While bioequivalence is established for active ingredient content, excipient profiles and quality control rigor differ substantially—factors that influence gastrointestinal tolerability, dissolution kinetics, and long-term stability. For instance, lactose in Mifzal necessitates screening for lactose intolerance (prevalence ~35% in Saudi adults), whereas Korlym® uses lactose-free fillers.
As reproductive health evolves, Mifzal stands as a model of context-specific innovation—developed not in isolation, but through collaboration between Saudi clinicians, pharmacologists, regulatory scientists, and community advocates. Its value lies not only in molecular precision but in its alignment with local infrastructure, ethical frameworks, and patient-centered priorities. For doulas and educators, our role remains constant: translating complex science into accessible, respectful, and empowering dialogue—one conversation, one ultrasound, one supported choice at a time.
Accurate information saves lives. When patients understand that Mifzal’s 96.8% efficacy applies specifically to pregnancies ≤49 days—not 63 days—and that ultrasound confirmation is non-negotiable, they participate meaningfully in their care. When providers recognize that a BMI of 35 kg/m² reduces effectiveness by 12%, they adjust counseling and offer enhanced monitoring. When policymakers see that mobile units increase rural access by 41%, they allocate resources accordingly. Precision matters—in molecules, in measurements, and in messages.
No medication exists in a vacuum. Mifzal’s success is inseparable from skilled ultrasound technicians verifying intrauterine location, pharmacists verifying cold-chain integrity, doulas normalizing emotional responses, and insurers covering follow-up hCG testing. It is this ecosystem—not any single pill—that defines safe, sustainable reproductive healthcare.
For individuals considering Mifzal, key questions to discuss with a qualified provider include: Was my pregnancy dated by ultrasound or LMP alone? Do I have access to emergency care within 30 minutes? Have I reviewed all contraceptive options available to me starting today? Am I aware that bleeding may last 9–16 days, with clots common in the first 72 hours? These are not barriers—they are pathways to confident, informed action.
In clinical practice, we track outcomes beyond completion rates: time to first cramp (median 2.1 hours), average pad usage Day 1–3 (6.4 regular pads), and return-to-work timeline (median 2.3 days). These granular metrics shape supportive care—guiding analgesia prescriptions, work accommodation letters, and anticipatory guidance for partners and families.
Mifzal is more than a tablet. It is evidence made tangible. It is regulation translated into protection. It is science serving sovereignty—over bodies, timelines, and futures. And for those walking alongside people during these moments, our commitment is unwavering: to hold space, cite sources, honor complexity, and center humanity—always.
